BRIEF—Judge overturns jury verdict against AbbVie in AndroGel case

A US district judge has overturned a $150 million verdict against US pharma firm AbbVie that was the first to result from lawsuits claiming the company fraudulently misrepresented the risks of its AndroGel testosterone replacement drug, according to media reports including Seeking Alpha.

"The irreconcilable conflict between the jury's finding of liability on the fraudulent misrepresentation claim and award of zero compensatory damages requires a new trial on this claim," the judge ruled.

Because the punitive damages award depended on the jury finding AbbVie liable, the judge also vacated the $150 million award; a new trial is now scheduled for March 5.